[Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)].
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004285:Dogs; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D007275:Injections, Intravenous; D007939:Leukemia L1210 / Q000188:drug therapy; D009052:Leukemia Virus, Murine; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D001357:Sarcoma, Avian / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013737:Testis / Q000187:drug effects; D014412:Tumor Virus Infections / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic
Etude toxicologique ET ACTIVIT'E ANTITUMORALE EXP'ERIMENTALE DE LA RUBIDOMYCINE (13.057 R.P.)